新加坡生物科技公司MIRXES-B（02629.HK）今日在香港联交所挂牌上市，股价表现亮眼。截至今日盘中，MIRXES-B股价大涨33.26%，引发市场广泛关注。
MIRXES-B是一家专注于微小核糖核酸（miRNA）技术的公司，致力于在亚洲市场提供疾病筛查诊断解决方案。公司此次IPO定价为每股23.3港元，募集资金净额约8.8亿港元。值得注意的是，MIRXES-B是全球首家也是唯一一家获得分子胃癌筛查IVD产品监管批准的公司，其核心产品GASTROClearTM已在新加坡成功商业化。
分析人士指出，MIRXES-B的强劲表现反映了投资者对生物科技和医疗诊断领域的高度关注。随着人口老龄化和健康意识的提升，早期疾病筛查市场潜力巨大。此外，近期港股IPO普遍表现良好，也为MIRXES-B的上市营造了有利氛围。不过，投资者也应注意到，该公司目前仍处于亏损状态，未来盈利能力仍有待观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.